Dexamethasone suppresses release of soluble TNF receptors by human monocytes concurrently with TNF-α suppression

Immunology and Cell Biology

Volumn 75, Issue 4, 1997, Pages 345-350

  Joyce, David A ^a,b   Kloda, Anna ^a   Steer, James H ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Dexamethasone; Human; Monocytes; TNF receptors; TNF

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; MONOCYTE; NORMAL HUMAN; PROTEIN SECRETION;

EID: 0030932013     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.53     Document Type: Article

References (32)

1. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann. Int. Med. 1993; 119: 1198-208.
2. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 1990; 172: 391-4.
3. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of Interleukin-1α, Interleukin-1β, and Interleukin-6: Mediation by decreased mRNA stability. Mol. Pharmacol. 1993; 43: 176-82.
4. Arend WP, Wegus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 1990; 85: 1694-7.
5. Joyce DA, Steer JH. Tumor necrosis factor-α and interleukin-1α stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes. J. Interferon Cytokine Res. 1995; 15: 947-54.
6. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl Acad. Sci. USA. 1990; 87: 3127-31.
7. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, IL-10 and IL-4, have contrasting effects on the release of soluble p75 TNF receptor by cultured human monocytes. Eur. J. Immunol. 1994; 24: 2699-705.
8. Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol 1994; 151: 1548-61.
9. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992; 175: 323-9.
10. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J. Immunol. 1993; 150: 2007-17.
11. Joyce DA, Steer JH, Kloda A. Dexamethasone antagonises IL-4 and IL-10-induced release of IL-1ra by monocytes but augments IL-4-, IL-10- and TGF-β-induced suppression of TNF-α release. J. Interferon Cytokine Res. 1996; 16: 513-19.
12. Arzt E, Sauer J, Pollmacher T et al. Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology 1994; 134: 672-77.
13. Roth J, Goebeler M, Erpenstein U, Sorg C. Differential regulation of the macrophage-specific antigen RM3/I by cyclosporine, azathioprine and dexamethasone. Transplantation 1994; 57: 127-33.
14. Joyce DA, Steer JH, Beilharz M, Stranger R. A system for assessment of monokine gene expression using human whole blood. Genet. Anal. Biomol. Eng. 1995; 12: 39-43.
15. Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins MA, Allison AC. Monoclonal antibodies to human recombinant interleukin 1 (IL 1)-β: Quantitation of IL-1β and inhibition of biological activity. J. Immunol. 1987; 138: 4236-42.
16. Phillips WG, Feldmann M, Breathnach SM, Brennan FM. Modulation of the IL-1 cytokine network in keratinocytes by intracellular IL-1α and IL-1 receptor antagonist. Clin. Exp. Immunol. 1995; 101: 177-82.
17. Meager A, Parti S, Leung H, Peil E, Mahon B. Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 1987; 6: 305-11.
18. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 1986; 95: 99-105.
19. Leeuwenberg JF, Dentener MA, Buurman WA. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14. LPS binding protein, and bactericidal/permeability-increasing protein. J. Immunol. 1994; 152: 5070-6.
20. Aderka D, Wysenbeek A, Engelmann H et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 1993; 36: 1111-20.
21. Aderka D, Engelmann H, Hornik V et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991; 51: 1-6.
22. Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992; 35: 1160-9.
23. Chikanza IC, Rouxlombard P, Dayer JM, Panayi GS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin. Exp. Immunol. 1993; 92: 19-22.
24. Arend WP. Interleukin-1 receptor antagonist. Adv. Immunol. 1993; 54: 167-227.
25. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 1993; 151: 6602-7.
26. Russell D, Tucker K, Kohno H, Thompson R, Schwab J. Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthritis Rheum. 1994; 37 (Suppl. 9): S279.
27. Levine SJ, Logun C, Chopra DP, Rhim JS, Shelhamer JH. Protein kinase C, interleukin-1 beta, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 1996; 14: 254-61.
28. 3 of the 75 kD-type A tumor necrosis receptor surface expression and mRNA level in human U397 cells. Eur. Cytokine Netw. 1991; 2: 355-60.
29. Roux-Lombard P, Modoux C, Dayer J-M. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during monocyte-macrophage differentiation: Influence of GM-CSF. Cytokine 1989; 1: 45-51.
30. Berger AE, Carter DB, Hankey SO, McEwan RN. Cytokine regulation of the Interleukin-1 receptor antagonist protein in U937 cells. Eur. J. Immunol. 1993; 23: 39-45.
31. Deleuran BW, Chu C, Field M et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: Implications for local actions of tumor necrosis factor-α. Arthritis Rheum. 1992; 35: 1170-8.
32. Koch AE, Kunkel SL, Chensue SW, Haines GK, Stricter RM. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin. Immunol. Immunopathol. 1992; 65: 23-9.